Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

David Camidge

Concepts (530)

Concepts are derived automatically from a person's publications.

Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Lung Neoplasms
190
2022
2184
31.200
Why?
Carcinoma, Non-Small-Cell Lung
147
2022
978
31.090
Why?
Protein Kinase Inhibitors
82
2022
858
13.800
Why?
Receptor Protein-Tyrosine Kinases
47
2022
268
11.880
Why?
Antineoplastic Agents
74
2021
2071
10.960
Why?
Pyrazoles
45
2021
390
8.580
Why?
Pyrimidines
31
2022
402
8.220
Why?
Pyridines
38
2021
483
7.810
Why?
Antineoplastic Combined Chemotherapy Protocols
39
2022
1397
6.860
Why?
Gene Rearrangement
25
2019
167
6.300
Why?
Organophosphorus Compounds
15
2022
78
6.290
Why?
ErbB Receptors
47
2022
549
5.850
Why?
Brain Neoplasms
27
2022
960
5.010
Why?
Protein-Tyrosine Kinases
25
2022
450
4.740
Why?
Drug Resistance, Neoplasm
31
2021
681
4.220
Why?
Proto-Oncogene Proteins c-met
20
2022
68
4.180
Why?
Proto-Oncogene Proteins
25
2022
716
3.410
Why?
Immunoconjugates
6
2021
93
3.290
Why?
Neoplasms
28
2021
2037
3.180
Why?
Carbazoles
12
2022
90
3.180
Why?
Piperidines
11
2022
176
2.890
Why?
Adenocarcinoma
16
2017
804
2.770
Why?
Humans
252
2022
113846
2.660
Why?
Small Cell Lung Carcinoma
13
2022
80
2.590
Why?
Mutation
48
2022
3447
2.560
Why?
Middle Aged
128
2021
28753
2.560
Why?
Acrylamides
12
2022
41
2.560
Why?
Clinical Trials as Topic
17
2022
1009
2.290
Why?
Biomarkers, Tumor
24
2021
1045
2.290
Why?
Molecular Targeted Therapy
14
2022
380
2.250
Why?
Aged
105
2021
20109
2.240
Why?
Thoracic Neoplasms
3
2019
35
2.150
Why?
Antibodies, Monoclonal, Humanized
18
2022
634
2.060
Why?
Oncogene Proteins, Fusion
8
2021
202
1.960
Why?
In Situ Hybridization, Fluorescence
15
2021
330
1.900
Why?
Male
136
2021
60993
1.860
Why?
Quinazolines
11
2017
244
1.830
Why?
Aged, 80 and over
58
2021
6796
1.820
Why?
Antibodies, Monoclonal
14
2021
1302
1.800
Why?
Female
136
2021
63035
1.760
Why?
Receptors, TNF-Related Apoptosis-Inducing Ligand
5
2013
39
1.750
Why?
Mesothelioma
4
2018
35
1.690
Why?
Neoplasm Staging
28
2021
1226
1.650
Why?
Erlotinib Hydrochloride
12
2022
70
1.640
Why?
Lactams, Macrocyclic
7
2021
61
1.620
Why?
Adult
95
2021
31979
1.570
Why?
Central Nervous System
4
2021
248
1.570
Why?
Radiosurgery
10
2022
298
1.530
Why?
Disease-Free Survival
26
2020
682
1.490
Why?
Gene Dosage
4
2018
148
1.480
Why?
Survival Rate
23
2021
1854
1.400
Why?
Maximum Tolerated Dose
20
2021
187
1.370
Why?
Clinical Trials, Phase I as Topic
3
2021
52
1.350
Why?
Imidazoles
4
2018
259
1.290
Why?
Lung Diseases, Interstitial
4
2020
407
1.280
Why?
Aniline Compounds
8
2022
65
1.280
Why?
Piperazines
3
2019
325
1.260
Why?
Proto-Oncogene Proteins p21(ras)
12
2019
241
1.240
Why?
Prognosis
27
2022
3544
1.220
Why?
Cell Cycle
6
2012
603
1.150
Why?
Oncogenes
4
2019
109
1.150
Why?
Treatment Outcome
41
2022
9002
1.140
Why?
Receptor, ErbB-2
9
2020
321
1.140
Why?
Proto-Oncogene Proteins c-ret
2
2021
25
1.090
Why?
Disease Progression
17
2022
2489
1.090
Why?
B7-H1 Antigen
4
2020
132
1.090
Why?
Trastuzumab
2
2021
95
1.090
Why?
Follow-Up Studies
25
2021
4906
1.070
Why?
Camptothecin
4
2020
87
1.060
Why?
Pleural Neoplasms
3
2018
23
1.050
Why?
Immunotherapy
5
2021
462
1.040
Why?
Glomerular Filtration Rate
3
2019
575
1.020
Why?
Neoplasm Metastasis
12
2020
616
1.010
Why?
Neuregulin-1
2
2021
46
0.990
Why?
Retrospective Studies
32
2022
11340
0.990
Why?
Apoptosis
7
2013
2675
0.980
Why?
Pyridazines
3
2019
57
0.970
Why?
Paclitaxel
9
2020
194
0.960
Why?
Hypogonadism
2
2013
74
0.960
Why?
Endpoint Determination
5
2018
69
0.960
Why?
Glutamates
6
2014
59
0.940
Why?
Medical Oncology
3
2021
189
0.930
Why?
Exons
8
2022
317
0.930
Why?
Guanine
6
2014
87
0.920
Why?
Carboplatin
11
2021
138
0.920
Why?
Response Evaluation Criteria in Solid Tumors
5
2021
13
0.910
Why?
Survival Analysis
11
2021
1414
0.890
Why?
ras Proteins
8
2014
155
0.870
Why?
Authorship
1
2021
42
0.870
Why?
Receptor, Fibroblast Growth Factor, Type 1
2
2018
59
0.860
Why?
Patient Selection
5
2019
694
0.850
Why?
Carcinoma, Renal Cell
2
2013
167
0.850
Why?
Dose-Response Relationship, Drug
13
2021
2229
0.830
Why?
Biomarkers
8
2019
3501
0.830
Why?
Antineoplastic Agents, Immunological
2
2019
154
0.820
Why?
Kidney
2
2019
1211
0.790
Why?
Lactams
7
2021
39
0.790
Why?
Testosterone
2
2013
307
0.790
Why?
Drug-Related Side Effects and Adverse Reactions
3
2020
214
0.780
Why?
Aminopyridines
7
2021
88
0.780
Why?
Neoplasm Recurrence, Local
4
2022
789
0.770
Why?
Gene Amplification
9
2019
107
0.750
Why?
Kidney Neoplasms
2
2013
325
0.740
Why?
Proto-Oncogene Proteins B-raf
4
2018
205
0.730
Why?
Cyclin-Dependent Kinases
2
2010
116
0.720
Why?
Thromboembolism
1
2018
104
0.710
Why?
Healthcare Disparities
2
2021
465
0.700
Why?
Young Adult
22
2020
10971
0.690
Why?
Kaplan-Meier Estimate
14
2020
872
0.680
Why?
Pyrazines
2
2019
86
0.680
Why?
Drug Administration Schedule
10
2017
825
0.680
Why?
Liver Neoplasms
2
2019
454
0.670
Why?
Central Nervous System Neoplasms
4
2022
124
0.670
Why?
Creatinine
2
2019
461
0.660
Why?
Receptors, Fibroblast Growth Factor
2
2016
62
0.630
Why?
Mouth Mucosa
2
2006
96
0.620
Why?
Hair
2
2006
69
0.610
Why?
Triazoles
2
2013
144
0.580
Why?
Cranial Irradiation
7
2022
73
0.580
Why?
Indoles
6
2021
357
0.570
Why?
DNA Copy Number Variations
5
2019
159
0.560
Why?
Nitrofurantoin
1
2014
7
0.560
Why?
Pemetrexed
6
2014
30
0.560
Why?
Anti-Infective Agents, Urinary
1
2014
14
0.560
Why?
Cystitis
1
2014
23
0.560
Why?
Cohort Studies
13
2021
5011
0.540
Why?
Lymphoma, Large-Cell, Anaplastic
1
2014
20
0.540
Why?
Crown Ethers
1
2013
4
0.540
Why?
Circulating Tumor DNA
3
2018
18
0.530
Why?
Taxoids
5
2016
94
0.530
Why?
Blood-Brain Barrier
2
2016
105
0.520
Why?
Carcinoma, Squamous Cell
5
2019
557
0.510
Why?
RNA, Messenger
3
2018
2857
0.500
Why?
Signal Transduction
8
2014
4923
0.500
Why?
Insulin-Like Growth Factor II
2
2009
23
0.490
Why?
Receptors, Platelet-Derived Growth Factor
1
2012
14
0.480
Why?
Organoplatinum Compounds
3
2012
42
0.480
Why?
Receptor, IGF Type 1
1
2012
59
0.470
Why?
Cell-Free Nucleic Acids
3
2022
23
0.470
Why?
Point Mutation
1
2013
258
0.470
Why?
Androgens
1
2013
156
0.460
Why?
Sulfonamides
5
2020
450
0.460
Why?
Translocation, Genetic
1
2012
120
0.460
Why?
Tissue Distribution
5
2020
383
0.460
Why?
Carcinoma, Large Cell
1
2011
16
0.450
Why?
Keratin-18
1
2010
12
0.430
Why?
Smoking
2
2018
1632
0.430
Why?
Apoptosis Regulatory Proteins
1
2011
219
0.430
Why?
Cell Proliferation
8
2014
2404
0.420
Why?
Adenocarcinoma, Bronchiolo-Alveolar
2
2016
19
0.420
Why?
Insulin-Like Growth Factor I
2
2009
280
0.420
Why?
Estrenes
1
2010
17
0.420
Why?
Lymphatic Metastasis
2
2009
302
0.410
Why?
Drug Therapy, Combination
1
2013
1004
0.410
Why?
Antimitotic Agents
1
2009
9
0.410
Why?
Benzamides
2
2022
186
0.410
Why?
Receptors, Somatomedin
1
2009
4
0.410
Why?
Estradiol
2
2010
452
0.400
Why?
Catheter Ablation
1
2012
316
0.390
Why?
Caspase 3
1
2010
256
0.390
Why?
Genetic Testing
2
2015
382
0.380
Why?
Antineoplastic Agents, Phytogenic
2
2001
192
0.380
Why?
Programmed Cell Death 1 Receptor
3
2019
182
0.380
Why?
Lung
4
2019
3637
0.380
Why?
Sulfones
4
2021
102
0.370
Why?
Mitosis
1
2009
193
0.370
Why?
Adolescent
12
2020
18736
0.370
Why?
Lymph Node Excision
1
2009
126
0.370
Why?
Oligonucleotides, Antisense
1
2008
107
0.360
Why?
Genotype
4
2021
2074
0.340
Why?
Chemoradiotherapy
2
2019
199
0.340
Why?
Cyclin-Dependent Kinase Inhibitor Proteins
1
2006
7
0.340
Why?
HIV
1
2008
206
0.340
Why?
Administration, Oral
8
2015
798
0.330
Why?
Quality of Life
5
2021
2136
0.330
Why?
Cell Line, Tumor
9
2019
2936
0.330
Why?
Immunohistochemistry
5
2022
1831
0.330
Why?
Etoposide
4
2021
166
0.330
Why?
Accidents
1
2007
42
0.330
Why?
Quinazolinones
3
2016
17
0.330
Why?
Ethics, Medical
1
2006
86
0.320
Why?
Cell Adhesion Molecules
2
2017
190
0.310
Why?
Pharmacology
1
2005
9
0.310
Why?
Pharmacokinetics
1
2005
36
0.310
Why?
Technology, Pharmaceutical
1
2005
32
0.310
Why?
Antigens, Neoplasm
2
2017
235
0.300
Why?
Cough
2
2017
96
0.290
Why?
DNA, Neoplasm
2
2019
171
0.290
Why?
Precision Medicine
4
2019
315
0.290
Why?
Mortality
1
2007
328
0.290
Why?
Registries
4
2021
1824
0.280
Why?
Time Factors
7
2021
7060
0.280
Why?
Immunoenzyme Techniques
3
2014
230
0.270
Why?
Phenylurea Compounds
2
2016
87
0.270
Why?
Cost-Benefit Analysis
3
2021
537
0.270
Why?
RNA
3
2019
776
0.270
Why?
Leukocytes, Mononuclear
1
2006
502
0.270
Why?
Radiotherapy Dosage
3
2017
252
0.260
Why?
Combined Modality Therapy
5
2017
1243
0.250
Why?
Prospective Studies
6
2022
6250
0.250
Why?
Tumor Burden
3
2018
281
0.250
Why?
Pyrroles
3
2012
199
0.240
Why?
Treatment Failure
3
2014
329
0.240
Why?
DNA Mutational Analysis
3
2019
420
0.240
Why?
Benzodiazepinones
1
2021
18
0.230
Why?
Nails, Malformed
1
2001
5
0.230
Why?
Indazoles
1
2022
68
0.230
Why?
Lymphoma, Follicular
1
2021
38
0.230
Why?
Breast Neoplasms
3
2020
1909
0.220
Why?
Fatigue
5
2015
293
0.220
Why?
Carcinoma, Small Cell
1
2001
175
0.220
Why?
Recurrence
3
2018
967
0.220
Why?
Research Design
5
2016
913
0.220
Why?
Epidermal Cyst
1
2000
12
0.220
Why?
Bevacizumab
2
2019
124
0.210
Why?
Policy
1
2021
70
0.210
Why?
Biopsy
3
2013
1065
0.210
Why?
Skin
1
2005
702
0.210
Why?
Retreatment
2
2017
66
0.210
Why?
Meningeal Neoplasms
1
2021
80
0.210
Why?
Radiodermatitis
1
2000
7
0.210
Why?
Neovascularization, Pathologic
3
2012
291
0.210
Why?
Quality-Adjusted Life Years
2
2021
114
0.210
Why?
Deglutition Disorders
1
2001
122
0.210
Why?
Standard of Care
1
2020
88
0.200
Why?
Oncogene Protein p21(ras)
1
2019
26
0.200
Why?
Proto-Oncogene Proteins c-bcl-2
2
2012
234
0.200
Why?
Suicide
1
2007
521
0.200
Why?
Lymphoma, B-Cell
1
2000
95
0.200
Why?
Lymphoma, Large B-Cell, Diffuse
1
2000
83
0.200
Why?
Consolidation Chemotherapy
1
2019
13
0.200
Why?
Diagnostic Imaging
1
2022
271
0.200
Why?
Organs at Risk
1
2019
32
0.200
Why?
Cisplatin
4
2014
284
0.200
Why?
Aminoquinolines
1
2019
18
0.200
Why?
Diarrhea
2
2017
178
0.200
Why?
Carcinoma, Lewis Lung
1
2019
13
0.190
Why?
Positron-Emission Tomography
4
2014
301
0.190
Why?
Animals
15
2019
35394
0.190
Why?
Oncogene Proteins
1
2019
67
0.190
Why?
Radiotherapy, Conformal
2
2017
69
0.190
Why?
Gene Fusion
1
2018
21
0.190
Why?
Antinematodal Agents
1
2018
6
0.190
Why?
Incidence
3
2020
2470
0.190
Why?
Vascular Endothelial Growth Factor A
3
2012
517
0.190
Why?
Clinical Trials, Phase II as Topic
1
2018
56
0.190
Why?
Clinical Trials, Phase III as Topic
1
2018
76
0.190
Why?
Drug Approval
1
2018
72
0.180
Why?
Gold
1
2019
105
0.180
Why?
Cytotoxicity, Immunologic
1
2018
218
0.180
Why?
Radiotherapy
3
2016
203
0.180
Why?
Hospitalization
1
2007
1678
0.180
Why?
Multivariate Analysis
2
2019
1599
0.170
Why?
Chemotherapy, Adjuvant
3
2022
325
0.170
Why?
Drowning
1
2017
11
0.170
Why?
MAP Kinase Signaling System
1
2019
320
0.170
Why?
Proportional Hazards Models
3
2020
1141
0.170
Why?
Thymus Neoplasms
1
2017
21
0.170
Why?
Thymoma
1
2017
32
0.170
Why?
Scotland
2
2007
14
0.170
Why?
Immunity, Cellular
1
2019
307
0.170
Why?
Receptors, Growth Factor
3
2011
57
0.170
Why?
Benzimidazoles
3
2018
147
0.170
Why?
Diagnosis, Differential
2
2014
1432
0.170
Why?
Nausea
1
2017
116
0.160
Why?
Head and Neck Neoplasms
1
2021
400
0.160
Why?
Headache
1
2017
114
0.160
Why?
Pleural Effusion, Malignant
1
2016
16
0.160
Why?
Decision Trees
1
2016
83
0.160
Why?
Centrosome
1
2016
67
0.160
Why?
Adjuvants, Immunologic
1
2017
234
0.160
Why?
Proto-Oncogene Proteins c-kit
1
2016
58
0.150
Why?
Real-Time Polymerase Chain Reaction
2
2014
366
0.150
Why?
Peritoneal Neoplasms
1
2016
59
0.150
Why?
Markov Chains
1
2016
127
0.150
Why?
Randomized Controlled Trials as Topic
2
2018
1136
0.150
Why?
Postoperative Care
1
2017
233
0.150
Why?
Pneumonia
1
2020
558
0.150
Why?
Chronic Disease
2
2014
1681
0.150
Why?
Neutropenia
4
2019
133
0.140
Why?
Radiotherapy, Adjuvant
2
2022
195
0.140
Why?
Risk Assessment
5
2015
3147
0.140
Why?
Drug Interactions
2
2013
423
0.140
Why?
Cryptogenic Organizing Pneumonia
1
2014
18
0.140
Why?
Magnetic Resonance Imaging
5
2018
3049
0.140
Why?
Structure-Activity Relationship
2
2018
576
0.140
Why?
Australia
2
2012
221
0.140
Why?
Thoracic Surgery, Video-Assisted
1
2014
34
0.140
Why?
Reverse Transcriptase Polymerase Chain Reaction
2
2014
1123
0.140
Why?
HIV Infections
1
2008
2487
0.140
Why?
Skin Neoplasms
1
2000
737
0.130
Why?
Vascular Endothelial Growth Factor Receptor-2
2
2013
86
0.130
Why?
Reproducibility of Results
3
2006
2905
0.130
Why?
Threonine
1
2013
50
0.130
Why?
Sex Hormone-Binding Globulin
1
2013
54
0.130
Why?
Sequence Analysis, DNA
2
2014
798
0.130
Why?
GTP Phosphohydrolases
1
2013
63
0.130
Why?
Sodium-Phosphate Cotransporter Proteins, Type IIb
1
2012
13
0.130
Why?
Dyspnea
1
2014
186
0.120
Why?
Focal Adhesion Kinase 2
1
2012
4
0.120
Why?
Disease Management
2
2020
606
0.120
Why?
Methionine
1
2013
155
0.120
Why?
HSP90 Heat-Shock Proteins
1
2013
74
0.120
Why?
Luteinizing Hormone
1
2013
188
0.120
Why?
Periodicals as Topic
1
2016
264
0.120
Why?
Heterozygote
1
2013
270
0.120
Why?
Focal Adhesion Kinase 1
1
2012
29
0.120
Why?
Serum Albumin
1
2013
161
0.120
Why?
Thiophenes
1
2013
107
0.120
Why?
Biomedical Research
2
2010
609
0.120
Why?
Follicle Stimulating Hormone
1
2013
220
0.120
Why?
Quinolines
1
2013
130
0.120
Why?
Glioma
1
2015
274
0.120
Why?
Niacinamide
1
2012
71
0.120
Why?
Genes, ras
1
2012
98
0.120
Why?
Platelet-Derived Growth Factor
1
2012
92
0.120
Why?
Biological Transport
1
2013
435
0.120
Why?
Hydroxamic Acids
1
2012
87
0.120
Why?
Fluorouracil
2
2012
139
0.120
Why?
Biomarkers, Pharmacological
1
2011
30
0.110
Why?
Radiation Pneumonitis
1
2011
29
0.110
Why?
Induction Chemotherapy
1
2011
53
0.110
Why?
Tomography, X-Ray Computed
4
2015
2380
0.110
Why?
Vimentin
1
2011
60
0.110
Why?
Immunosuppressive Agents
1
2016
676
0.110
Why?
Hyperglycemia
1
2015
336
0.110
Why?
Phytotherapy
1
2011
69
0.110
Why?
Genes, bcl-2
1
2011
21
0.110
Why?
Area Under Curve
2
2012
328
0.110
Why?
High-Throughput Nucleotide Sequencing
3
2019
446
0.110
Why?
Blotting, Western
2
2014
1316
0.110
Why?
X-Linked Inhibitor of Apoptosis Protein
1
2010
14
0.110
Why?
Heptanoic Acids
1
2011
68
0.110
Why?
Deoxycytidine
2
2011
146
0.110
Why?
Multicenter Studies as Topic
1
2011
222
0.110
Why?
Amino Acid Chloromethyl Ketones
1
2010
32
0.110
Why?
Models, Molecular
2
2018
1604
0.110
Why?
Cysteine Proteinase Inhibitors
1
2010
60
0.110
Why?
In Situ Nick-End Labeling
1
2010
138
0.110
Why?
Alcohol Drinking
1
2017
721
0.110
Why?
Histone Deacetylase Inhibitors
1
2012
201
0.100
Why?
Caspase Inhibitors
1
2010
96
0.100
Why?
Cadherins
1
2011
191
0.100
Why?
Cannabinoids
1
2011
114
0.100
Why?
Insulin-Like Growth Factor Binding Proteins
1
2009
27
0.100
Why?
Rats
2
2010
6387
0.100
Why?
Immunoblotting
1
2010
375
0.100
Why?
Cognition
2
2016
964
0.100
Why?
Epithelial-Mesenchymal Transition
1
2011
169
0.100
Why?
Pharmacogenetics
1
2010
170
0.100
Why?
Genetic Predisposition to Disease
1
2018
2424
0.100
Why?
Xenograft Model Antitumor Assays
3
2019
788
0.100
Why?
Demography
1
2010
294
0.100
Why?
Protein Structure, Tertiary
1
2012
906
0.090
Why?
Weight Loss
1
2014
694
0.090
Why?
Dogs
1
2010
472
0.090
Why?
Floxuridine
1
2008
8
0.090
Why?
Protein Kinase C beta
1
2008
29
0.090
Why?
Radiotherapy Planning, Computer-Assisted
1
2009
127
0.090
Why?
United States
5
2022
12329
0.090
Why?
Capecitabine
1
2008
43
0.090
Why?
Marijuana Smoking
1
2011
226
0.090
Why?
Species Specificity
1
2010
649
0.090
Why?
RNA Interference
1
2010
515
0.090
Why?
Double-Blind Method
2
2016
1673
0.090
Why?
Medical Records
1
2009
182
0.090
Why?
Risk Factors
4
2019
9050
0.090
Why?
Angiogenesis Inhibitors
1
2010
224
0.090
Why?
Clinical Decision-Making
2
2022
274
0.090
Why?
Polymerase Chain Reaction
1
2011
1100
0.090
Why?
Health Services Accessibility
1
2014
777
0.090
Why?
Enzyme-Linked Immunosorbent Assay
1
2010
909
0.090
Why?
Everolimus
2
2020
57
0.090
Why?
Salvage Therapy
2
2019
137
0.090
Why?
TNF-Related Apoptosis-Inducing Ligand
1
2007
68
0.080
Why?
Electronic Health Records
1
2013
670
0.080
Why?
Practice Guidelines as Topic
1
2016
1529
0.080
Why?
Antibiotics, Antineoplastic
1
2008
128
0.080
Why?
Retinoblastoma Protein
1
2006
54
0.080
Why?
Scalp
1
2006
26
0.080
Why?
Sensitivity and Specificity
2
2018
1930
0.080
Why?
Colorectal Neoplasms
1
2013
584
0.080
Why?
Receptors, Vascular Endothelial Growth Factor
1
2006
104
0.080
Why?
Placebos
1
2006
216
0.080
Why?
Cannabis
1
2011
292
0.080
Why?
Tumor Suppressor Protein p53
1
2010
465
0.080
Why?
Membrane Proteins
1
2013
1098
0.080
Why?
Brain
1
2018
2686
0.080
Why?
Cetuximab
2
2017
95
0.080
Why?
Protein Kinase C
1
2008
354
0.080
Why?
Neoplasm Proteins
1
2009
447
0.080
Why?
Receptors, Estrogen
1
2008
399
0.080
Why?
Hair Follicle
1
2005
55
0.070
Why?
Melanocytes
1
2005
67
0.070
Why?
Cell Line
1
2012
3016
0.070
Why?
Cross-Over Studies
1
2006
484
0.070
Why?
Reference Values
1
2006
877
0.070
Why?
Tumor Cells, Cultured
2
2019
1041
0.070
Why?
Monocytes
1
2008
517
0.070
Why?
Safety
1
2006
319
0.070
Why?
Class I Phosphatidylinositol 3-Kinases
2
2014
74
0.070
Why?
Specimen Handling
1
2005
176
0.070
Why?
Risk
1
2007
943
0.070
Why?
Models, Biological
1
2012
1845
0.070
Why?
Delivery of Health Care
1
2010
695
0.070
Why?
Phosphorylation
1
2008
1742
0.060
Why?
MAP Kinase Kinase 1
2
2014
72
0.060
Why?
Phosphatidylinositol 3-Kinases
2
2014
352
0.060
Why?
Pharyngeal Diseases
1
2001
18
0.060
Why?
Heparin, Low-Molecular-Weight
1
2021
27
0.060
Why?
Gene Expression Regulation, Neoplastic
2
2019
1210
0.060
Why?
Esophageal Diseases
1
2001
28
0.060
Why?
Opportunistic Infections
1
2001
53
0.060
Why?
Asia
1
2021
56
0.060
Why?
Mediastinal Neoplasms
1
2001
41
0.060
Why?
Sex Characteristics
1
2006
662
0.060
Why?
Gastrointestinal Neoplasms
1
2001
56
0.060
Why?
United States Food and Drug Administration
1
2022
179
0.060
Why?
Mutagenesis, Insertional
1
2021
63
0.060
Why?
Neoplasms, Second Primary
1
2001
75
0.060
Why?
Brain Stem Neoplasms
1
2001
79
0.050
Why?
Surveys and Questionnaires
1
2013
4625
0.050
Why?
Carbon Monoxide
1
2020
72
0.050
Why?
Europe
1
2021
351
0.050
Why?
Thrombocytopenia
2
2012
184
0.050
Why?
Focal Adhesion Protein-Tyrosine Kinases
1
2019
29
0.050
Why?
Ipilimumab
1
2019
33
0.050
Why?
Comparative Effectiveness Research
1
2020
143
0.050
Why?
Lymphopenia
1
2019
57
0.050
Why?
Mice
4
2019
15641
0.050
Why?
Drug Monitoring
1
2020
191
0.050
Why?
Age Factors
1
2007
3330
0.050
Why?
Leukocyte Count
1
2019
325
0.050
Why?
Organoids
1
2019
60
0.050
Why?
Liquid Biopsy
1
2018
6
0.050
Why?
Genes, erbB-1
1
2018
22
0.050
Why?
Lymphocytes, Tumor-Infiltrating
1
2019
112
0.050
Why?
Radiation Dosage
1
2019
144
0.040
Why?
Radiotherapy, Intensity-Modulated
1
2019
132
0.040
Why?
Feasibility Studies
1
2020
739
0.040
Why?
Topoisomerase I Inhibitors
1
2017
14
0.040
Why?
DNA Topoisomerases, Type I
1
2017
14
0.040
Why?
Immune System
1
2019
198
0.040
Why?
Practice Patterns, Physicians'
1
2006
1214
0.040
Why?
Intention to Treat Analysis
1
2017
74
0.040
Why?
Lymphocytes
1
2019
392
0.040
Why?
Exanthema
1
2017
63
0.040
Why?
Exosomes
1
2018
80
0.040
Why?
Hyperphosphatemia
1
2016
12
0.040
Why?
Palliative Care
2
2014
631
0.040
Why?
Genetic Heterogeneity
1
2016
61
0.040
Why?
Mice, Inbred BALB C
1
2019
1326
0.040
Why?
Myalgia
1
2015
16
0.040
Why?
Creatine Kinase
1
2015
90
0.040
Why?
Karnofsky Performance Status
1
2015
38
0.040
Why?
Drug Therapy
1
2016
82
0.040
Why?
Tumor Microenvironment
1
2019
369
0.040
Why?
Aspartate Aminotransferases
1
2015
102
0.040
Why?
Alanine Transaminase
1
2015
151
0.040
Why?
Edema
1
2015
116
0.040
Why?
Constipation
1
2015
71
0.040
Why?
Heart
1
2019
685
0.040
Why?
Gonanes
1
2014
28
0.040
Why?
Proto-Oncogenes
1
2014
31
0.040
Why?
Texas
1
2014
185
0.030
Why?
Multiplex Polymerase Chain Reaction
1
2014
38
0.030
Why?
United Kingdom
1
2014
246
0.030
Why?
Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
1
2014
164
0.030
Why?
Epidermal Growth Factor
1
2013
162
0.030
Why?
Amino Acid Substitution
1
2014
309
0.030
Why?
PTEN Phosphohydrolase
1
2014
138
0.030
Why?
Inhibitory Concentration 50
1
2013
88
0.030
Why?
Vision Disorders
1
2014
122
0.030
Why?
Computational Biology
1
2018
674
0.030
Why?
Recombination, Genetic
1
2014
177
0.030
Why?
Syndecan-4
1
2012
9
0.030
Why?
Neutrophils
1
2019
1324
0.030
Why?
Antigens, Differentiation, B-Lymphocyte
1
2012
44
0.030
Why?
Sirolimus
1
2013
182
0.030
Why?
Pyrimidinones
1
2013
89
0.030
Why?
Leucovorin
1
2012
42
0.030
Why?
Guidelines as Topic
1
2014
286
0.030
Why?
Cytochrome P-450 CYP3A Inhibitors
1
2012
19
0.030
Why?
Metabolic Clearance Rate
1
2012
140
0.030
Why?
Mice, SCID
1
2013
363
0.030
Why?
Midazolam
1
2012
52
0.030
Why?
Pyridones
1
2013
107
0.030
Why?
Proto-Oncogene Proteins c-akt
1
2014
442
0.030
Why?
Cytochrome P-450 CYP3A
1
2012
60
0.030
Why?
Biological Availability
1
2011
159
0.030
Why?
Nonlinear Dynamics
1
2012
91
0.030
Why?
Databases, Factual
1
2017
1206
0.030
Why?
Gene Frequency
1
2013
572
0.030
Why?
Fluorodeoxyglucose F18
1
2012
130
0.030
Why?
Receptor, ErbB-4
1
2011
19
0.030
Why?
Mice, Nude
1
2013
700
0.030
Why?
Canada
1
2012
336
0.030
Why?
Mutation, Missense
1
2013
324
0.030
Why?
Genetic Association Studies
1
2013
415
0.030
Why?
Histocompatibility Antigens Class II
1
2012
382
0.030
Why?
Radiopharmaceuticals
1
2012
207
0.030
Why?
MAP Kinase Kinase 2
1
2010
29
0.030
Why?
Capsules
1
2010
41
0.030
Why?
Serine Endopeptidases
1
2010
107
0.030
Why?
Meta-Analysis as Topic
1
2011
154
0.030
Why?
Molecular Diagnostic Techniques
1
2011
95
0.030
Why?
Socioeconomic Factors
1
2014
1211
0.030
Why?
Vascular Endothelial Growth Factor Receptor-1
1
2010
69
0.030
Why?
Cell Survival
1
2013
1188
0.030
Why?
Alopecia
1
2009
31
0.030
Why?
Microtubule-Associated Proteins
1
2010
213
0.020
Why?
Infusions, Intravenous
1
2010
412
0.020
Why?
Precancerous Conditions
1
2010
166
0.020
Why?
Mice, Inbred C57BL
1
2019
5249
0.020
Why?
Hormone Replacement Therapy
1
2008
80
0.020
Why?
Anemia
1
2009
166
0.020
Why?
Substrate Specificity
1
2008
405
0.020
Why?
Enzyme Inhibitors
1
2012
945
0.020
Why?
Evidence-Based Medicine
1
2012
728
0.020
Why?
California
1
2008
369
0.020
Why?
DNA Repair
1
2008
187
0.020
Why?
Cell Cycle Proteins
1
2010
574
0.020
Why?
Early Detection of Cancer
1
2010
304
0.020
Why?
Neoplastic Stem Cells
1
2010
331
0.020
Why?
Pain
1
2011
745
0.020
Why?
DNA Damage
1
2008
373
0.020
Why?
Genome-Wide Association Study
1
2010
1141
0.020
Why?
Colorado
1
2014
4581
0.020
Why?
MicroRNAs
1
2010
626
0.020
Why?
Predictive Value of Tests
1
2008
2025
0.020
Why?
Camidge's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
_
Co-Authors Expand Description
_
Similar People Expand Description
_
Same Department Expand Description
Physical Neighbors Expand Description
_

Copyright © 2022 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)